286 related articles for article (PubMed ID: 26043217)
1. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Rashidi A; Cashen AF
Future Oncol; 2015; 11(11):1659-64. PubMed ID: 26043217
[TBL] [Abstract][Full Text] [Related]
2. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Campbell P; Thomas CM
J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
[TBL] [Abstract][Full Text] [Related]
3. Belinostat for the treatment of peripheral T-cell lymphomas.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 May; 50(5):337-45. PubMed ID: 24918834
[TBL] [Abstract][Full Text] [Related]
4. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
[TBL] [Abstract][Full Text] [Related]
5. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
[TBL] [Abstract][Full Text] [Related]
6. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
Marchi E; Raufi AG; O'Connor OA
Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
Lee HZ; Kwitkowski VE; Del Valle PL; Ricci MS; Saber H; Habtemariam BA; Bullock J; Bloomquist E; Li Shen Y; Chen XH; Brown J; Mehrotra N; Dorff S; Charlab R; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
Clin Cancer Res; 2015 Jun; 21(12):2666-70. PubMed ID: 25802282
[TBL] [Abstract][Full Text] [Related]
8. Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.
Reimer P; Chawla S
J Hematol Oncol; 2013 Sep; 6():69. PubMed ID: 24020452
[TBL] [Abstract][Full Text] [Related]
9. Belinostat: first global approval.
Poole RM
Drugs; 2014 Sep; 74(13):1543-54. PubMed ID: 25134672
[TBL] [Abstract][Full Text] [Related]
10. Development of new agents for peripheral T-cell lymphoma.
Ito Y; Makita S; Tobinai K
Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
[TBL] [Abstract][Full Text] [Related]
11. Belinostat (Beleodaq) for peripheral T-Cell lymphoma.
Med Lett Drugs Ther; 2015 Apr; 57(1467):e66-7. PubMed ID: 25988963
[No Abstract] [Full Text] [Related]
12. Belinostat: clinical applications in solid tumors and lymphoma.
Molife LR; de Bono JS
Expert Opin Investig Drugs; 2011 Dec; 20(12):1723-32. PubMed ID: 22046971
[TBL] [Abstract][Full Text] [Related]
13. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.
Broccoli A; Argnani L; Zinzani PL
Cancer Treat Rev; 2017 Nov; 60():120-129. PubMed ID: 28946015
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors: novel agents in cancer treatment.
Glass E; Viale PH
Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
17. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
[TBL] [Abstract][Full Text] [Related]
18. UGT genotyping in belinostat dosing.
Goey AK; Figg WD
Pharmacol Res; 2016 Mar; 105():22-7. PubMed ID: 26773202
[TBL] [Abstract][Full Text] [Related]
19. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
[TBL] [Abstract][Full Text] [Related]
20. Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review.
Sawas A; Radeski D; O'Connor OA
Ther Adv Hematol; 2015 Aug; 6(4):202-8. PubMed ID: 26288714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]